RESUMO
The reaction of [(Me(3)Si)(2)N](2)S with an equimolar amount of SeCl(4) in dioxane at 50 degrees C affords [(Se(2)SN(2))Cl](2) (1) in excellent yield. Crystals of 1 are orthorhombic, space group Pbca, with a = 8.5721(7) A, b = 7.8336(6) A, c = 15.228(1) A, and Z = 8. The crystal structure contains two planar Se(2)SN(2)(*)(+) rings which are linked by intermolecular Se.Se interactions [d(Se-Se) = 3.0690(7) A]. The EI mass spectrum shows Se(2)SN(2)(*)(+) as the fragment of highest mass. Both the (14)N and (77)Se NMR spectra show a single resonance (-52 and 1394 ppm, respectively). The solid [(Se(2)SN(2))Cl](2) gives a strong ESR signal indicating the presence of a Se(2)SN(2)(*)(+) radical. The Raman spectrum was assigned through normal coordinate treatment involving a general valence force field. The vibrational analysis yielded a good agreement between the observed and calculated wavenumbers.
RESUMO
OBJECTIVE: Evaluation of the transplacental transfer and placental metabolism of sulindac, its active sulfide metabolite, and indomethacin, drugs used as tocolytic agents, in dual recirculating human placental perfusion. STUDY DESIGN: Term placentas were obtained with maternal consent immediately after delivery. Drugs were added to the maternal reservoir, together with antipyrine as a reference compound, and disappearance from the maternal circulation and appearance in the fetal circulation were followed up for 2 hours in 4 experiments for each compound. Drug concentrations were analyzed by high-performance liquid chromatography. RESULTS: The fetal/maternal concentration ratios after 2-hour perfusions were 0. 34 +/- 0.19 (mean +/- SD, sulindac), 0.54 +/- 0.17 (sulfide), and 0. 45 +/- 0.16 (indomethacin), and the fetal-maternal transfer percentages at 2 hours were 11.6 +/- 5.9 (sulindac), 18.2 +/- 5.2 (sulfide), and 15.3 +/- 4.5 (indomethacin). No metabolism of sulindac or indomethacin was detected. CONCLUSION: Sulindac sulfide, formed through hepatic metabolism, reaches the fetus in higher concentrations than does sulindac or indomethacin. Neither sulindac nor indomethacin is metabolized by the human placenta.
